Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland
Micha T. Maeder, Tabea König, Sanja Bogdanovic, Irene Schneider, Werner Eugster, Peter Ammann, Marius König, Jürg Beer & Hans Rickli
AIM OF THE STUDY
The quality of VKA anticoagulation in Switzerland is highly variable. Importantly, only 60% of patients achieve a TTR ≥65%, which is currently considered to be the minimal acceptable TTR required for VKA therapy. There are few clinical predictors of a good VKA anticoagulation quality. These data may represent a novel basis for decision making regarding the choice of anticoagulation for atrial fibrillation in Switzerland.
|citation||Maeder M T, König T, Bogdanovic S, Schneider I, Eugster W, Ammann P, König M, Beer J, Rickli H. Quality of vitamin K antagonist oral anticoagulation in 322 patients with atrial fibrillation - real-life data from a survey in Eastern Switzerland. Swiss Med Wkly 2017; 147:w14503.|
|type||journal paper/review (English)|
|date of publishing||06-10-2017|
|journal title||Swiss Med Wkly (147)|